Status asthmaticus
Drug research and approvals for status asthmaticus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 1 studies of status asthmaticus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 1
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for…NCT07455396 · Phase 2 · Johns Hopkins All Children's Hospital · starts Aug 1, 2026
Phase 3 1
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
Phase 2 6
- AlbuterolBeta-2 adrenergic receptor agonist
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- BudesonideGlucocorticoid receptor agonist
- BedoradrineBeta-2 adrenergic receptor agonist
- OxygenEssential for cellular homeostasis
- Helium
Phase 1 or earlier 2
- IpratropiumMuscarinic acetylcholine receptor M3 antagonist
- PrednisoneGlucocorticoid receptor agonist
How its trials ended
38 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 14% met their primary endpoint, 0% missed it and 86% stopped early.
- Completed, result not reported1539%
- Stopped: other or unclear924%
- Status unknown718%
- Stopped: enrollment or feasibility38%
- Met its primary endpoint25%
- Ongoing25%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA